Capricor Therapeutics Sees Unusually Large Options Volume (NASDAQ:CAPR)

Capricor Therapeutics Inc (NASDAQ:CAPR) saw some unusual options trading on Tuesday. Investors purchased 13,044 call options on the stock. This is an increase of 748% compared to the average volume of 1,538 call options.

Insider Activity at Capricor Therapeutics

In related news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the business’s stock in a transaction dated Friday, September 20th. The shares were purchased at an average price of $5.36 per share, for a total transaction of $14,999,997.52. Following the completion of the acquisition, the insider now directly owns 7,090,351 shares in the company, valued at approximately $38,004,281.36. The transaction was disclosed in a document filed with the SEC, which is available through this link. 12.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Capricor Therapeutics

A number of institutional investors have recently modified their holdings of CAPR. BNP Paribas Financial Markets acquired a new stake in Capricor Therapeutics in the 1st quarter valued at $40,000. Main Street Financial Solutions LLC lifted its holdings in Capricor Therapeutics by 37.5% during the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 7,500 shares in the last quarter. Rhumbline Advisers acquired a new stake in shares of Capricor Therapeutics in the second quarter valued at about $147,000. Bank of New York Mellon Corp increased its stake in shares of Capricor Therapeutics by 12.8% during the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after purchasing an additional 9,040 shares in the last quarter. Finally, Marshall Wace LLP acquired a new position in shares of Capricor Therapeutics during the 2nd quarter worth about $426,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

CAPR has been the subject of a number of research reports. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Capricor Therapeutics in a research report on Tuesday, September 24th. Maxim Group lifted their target price on Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, September 25th. Oppenheimer reiterated an “outperform” rating and issued a $15.00 price target on shares of Capricor Therapeutics in a report on Monday, September 23rd. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $8.00 price objective on shares of Capricor Therapeutics in a research note on Friday, September 20th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $22.60.

Capricor Therapeutics Price Performance

NASDAQ:CAPR traded down $1.36 during trading hours on Tuesday, reaching $13.85. The company had a trading volume of 8,735,676 shares, compared to its average volume of 896,326. Capricor Therapeutics has a 1-year low of $2.68 and a 1-year high of $18.14. The business’s 50 day moving average price is $5.01 and its 200-day moving average price is $5.36. The firm has a market cap of $442.91 million, a PE ratio of -19.66 and a beta of 3.92.

Capricor Therapeutics (NASDAQ:CAPR) last posted its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.03). Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. The firm had revenue of $3.97 million during the quarter, compared to analyst estimates of $4.51 million. On average, analysts expect that Capricor Therapeutics will post -1.14 earnings per share for the current fiscal year.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.